| Literature DB >> 33514825 |
Mikail Dogan1, Lina Kozhaya1, Lindsey Placek1, Courtney Gunter1, Mesut Yigit1, Rachel Hardy1, Matthew Plassmeyer2, Paige Coatney2, Kimberleigh Lillard2, Zaheer Bukhari3, Michael Kleinberg4, Chelsea Hayes5, Moshe Arditi6, Ellen Klapper5, Noah Merin7, Bruce Tsan-Tang Liang4, Raavi Gupta3, Oral Alpan2, Derya Unutmaz8,9.
Abstract
Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n = 115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.Entities:
Year: 2021 PMID： 33514825 DOI： 10.1038/s42003-021-01649-6
Source DB: PubMed Journal: Commun Biol ISSN： 2399-3642